Prescription DTx, Explained: The 2026 Field Guide
What prescription dtx covers, why it matters in 2026, and the numbers decision-makers should know.
Executives keep asking the same question about prescription dtx. FDA-regulated software treatments and the prescription model. This explainer sets out what the category actually covers, why it has moved to the center of digital therapeutics strategy, and the numbers every decision-maker should have at hand.
What it covers
FDA-regulated software treatments and the prescription model. In practice, that spans the vendors building the technology, the health systems and payers deploying it, and the regulators writing the rules around it. The category sits inside our broader Digital Therapeutics coverage, and its daily developments stream into the live Prescription DTx feed.
Why it matters in 2026
Consider the current numbers: boehringer Ingelheim put $50 million into Click Therapeutics to commercialize its schizophrenia DTx (our coverage).
Meanwhile, a Canadian randomized trial showed digital CBT-I built for adults 65+ meaningfully cut insomnia and anxiety (our coverage).
Meanwhile, there are 192 FDA-cleared digital therapeutics devices, but only seven are currently eligible for Medicare DMHT payment.
What to watch next
Three signals will tell you where prescription dtx goes from here: the reimbursement decisions now moving through CMS and commercial payers, the consolidation pattern as larger platforms absorb point solutions, and the evidence base - peer-reviewed results increasingly separate durable categories from demo-ware.
The bottom line
The direction of travel is clear; the pace will be set by reimbursement and by the evidence base now accumulating. For the latest developments, follow our continuously updated Prescription DTx topic page.